CenterBook Partners LP Sells 113,525 Shares of Royalty Pharma plc (NASDAQ:RPRX)

CenterBook Partners LP trimmed its position in Royalty Pharma plc (NASDAQ:RPRX) by 52.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 104,735 shares of the biopharmaceutical company’s stock after selling 113,525 shares during the period. CenterBook Partners LP’s holdings in Royalty Pharma were worth $2,672,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in RPRX. Norges Bank purchased a new position in shares of Royalty Pharma in the 4th quarter worth approximately $124,498,000. Swedbank AB lifted its holdings in Royalty Pharma by 10.3% during the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock worth $310,308,000 after acquiring an additional 1,136,800 shares during the period. Raymond James Financial Inc. purchased a new position in Royalty Pharma in the fourth quarter worth $19,990,000. New South Capital Management Inc. grew its stake in Royalty Pharma by 19.9% in the 4th quarter. New South Capital Management Inc. now owns 2,957,125 shares of the biopharmaceutical company’s stock valued at $75,436,000 after purchasing an additional 490,754 shares during the period. Finally, Russell Investments Group Ltd. increased its position in shares of Royalty Pharma by 32.0% during the 4th quarter. Russell Investments Group Ltd. now owns 1,855,791 shares of the biopharmaceutical company’s stock valued at $47,319,000 after purchasing an additional 449,551 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Trading Up 4.6 %

Shares of RPRX opened at $32.27 on Thursday. The firm has a market cap of $18.60 billion, a P/E ratio of 22.26, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $34.20. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The business has a 50-day moving average of $32.49 and a 200 day moving average of $29.08.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, research analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on RPRX shares. TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. Citigroup reiterated a “buy” rating on shares of Royalty Pharma in a research note on Friday, March 28th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.